| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/767843/2011 (23.9.11) |
| Publication Date | 23/09/2011 |
| Content Type | News |
|
The European Medicines Agency (EMA), confirmed in September 2011, that the benefit-risk balance for Revlimid (lenalidomide) remained positive within its approved patient population but advised doctors of the risk of new cancers as a result of treatment with the medicine. Revlimid is used in combination with dexamethasone (an anti-inflammatory medicine) to treat adult patients with multiple myeloma whose disease has been treated at least once in the past. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001343.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
